114 / 1631
▪
Bespoke individualised therapies – complex logistics
▪
Automated manufacture
▪
Expensive
▪
Allogeneic CAR-T
▪
Antigen escape relapses
▪
Targeting multiple antigens – single CAR construct, multiple CAR constructs, multiple cellular products
▪
Clinical challenges
▪
Durability of responses?
▪
Defining cell dose, optimal lymphodepletion
▪
Positioning in overall treatment pathway
▪
Optimal approach to limit or manage toxicities
CAR19: challenges